Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

关于 Capivasertib(卡帕塞替尼) API

Product
  • CAS 编号

    1143532‑39‑1

  • API 技术

    Small‑molecule synthetic API

  • 剂型

    片剂

  • Dr Reddy's 开发状态

    开发中

Mechanism of action

Capivasertib inhibits all three AKT isoforms (AKT1, AKT2, AKT3).
AKT is a central signaling node in the PI3K/AKT/mTOR pathway, regulating cell proliferation, survival, and metabolism.
By blocking AKT kinase activity, capivasertib:

Inhibits phosphorylation of downstream AKT substrates
Suppresses tumor cell growth and survival
Overcomes resistance to endocrine therapy driven by PIK3CA mutations, AKT1 mutations, or PTEN loss


Demonstrates antitumor activity both as monotherapy and in combination with endocrine agents.

Indication

"Approved indication (FDA):

In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)‑positive, HER2‑negative, locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, following disease progression on endocrine therapy." 
 

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Capivasertib(卡帕塞替尼)
Select Regulatory Requirements
Select Purpose

Related APIs

Adagrasib(阿达格拉西布)

Oncology(肿瘤)

arrow

Fruquintinib(呋喹替尼)

Oncology(肿瘤)

arrow

Tucatinib(图卡替尼)

Oncology(肿瘤)

arrow

Ripretinib(瑞派替尼)

Oncology(肿瘤)

arrow

Cabozantinib Hydrochloride(盐酸卡博替尼)

Oncology(肿瘤)

arrow

Cabozantinib S‑Malate(苹果酸卡博替尼)

Oncology(肿瘤)

arrow

Carfilzomib(卡非佐米)

Oncology(肿瘤)

arrow

Deucravacitinib(‌氘可来昔替尼)

Oncology(肿瘤)

arrow

Acalabrutinib(阿卡替尼)

Oncology(肿瘤)

arrow

Capivasertib(卡帕塞替尼)

Oncology(肿瘤)

arrow

Lenvatinib Mesylate (Form C and MIBK Solvate)(甲磺酸仑伐替尼,C 型及 MIBK 溶合物)

Oncology(肿瘤)

arrow

Abiraterone Acetate(醋酸阿比特龙)

Oncology(肿瘤)

arrow

Apalutamide (Amorphous and Form B)(阿帕他胺,无定形及 B晶 型)

Oncology(肿瘤)

arrow

Zoledronic Acid(唑来膦酸)

Oncology(肿瘤)

arrow

Azacitidine(阿扎胞苷)

Oncology(肿瘤)

arrow

Bendamustine Hydrochloride(盐酸苯达莫司汀)

Oncology(肿瘤)

arrow

Relugolix(瑞卢戈利)

Oncology(肿瘤)

arrow

Bortezomib(硼替佐米)

Oncology(肿瘤)

arrow

Cabazitaxel(卡巴他赛)

Oncology(肿瘤)

arrow

Capecitabine(卡培他滨)

Oncology(肿瘤)

arrow

Pomalidomide(泊马度胺)

Oncology(肿瘤)

arrow

Pemetrexed Disodium Heptahydrate(培美曲塞二钠七水合物)

Oncology(肿瘤)

arrow

Pazopanib(帕唑帕尼)

Oncology(肿瘤)

arrow

Palbociclib(哌柏西利)

Oncology(肿瘤)

arrow

Dasatinib Monohydrate(达沙替尼一水合物)

Oncology(肿瘤)

arrow

Olaparib (Form A)(奥拉帕利,A 晶型)

Oncology(肿瘤)

arrow

Decitabine(地西他滨)

Oncology(肿瘤)

arrow

Nilotinib Hydrochloride(盐酸尼洛替尼)

Oncology(肿瘤)

arrow

Midostaurin (Amorphous and Form II)(米哚妥林,无定形及 II 晶型)

Oncology(肿瘤)

arrow

Enzalutamide(恩扎卢胺)

Oncology(肿瘤)

arrow

Eribulin Mesylate(甲磺酸艾立布林)

Oncology(肿瘤)

arrow

Gemcitabine Hydrochloride(盐酸吉西他滨)

Oncology(肿瘤)

arrow

Lenalidomide (Form A)(来那度胺,A 晶型)

Oncology(肿瘤)

arrow

Lomustine(洛莫司汀)

Oncology(肿瘤)

arrow
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.